Immunome Inc (IMNM)
15.75
+0.78
(+5.21%)
USD |
NASDAQ |
May 03, 15:04
Immunome Revenue (TTM): 14.02M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 14.02M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
14.02M
Minimum
Dec 2023
14.02M
Maximum
Dec 2023
14.02M
Average
14.02M
Median
Dec 2023
Revenue (TTM) Benchmarks
Ayala Pharmaceuticals Inc | -- |
Tenax Therapeutics Inc | -- |
GE HealthCare Technologies Inc | 19.50B |
Exelixis Inc | 1.847B |
Puma Biotechnology Inc | 235.64M |